化合物 SCR7|T3340|TargetMol

SCR7
1533426-72-0

￥560 1mg 起订

￥1900 5mg 起订

￥3220 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 SCR7

英文名称：: SCR7

CAS号：: 1533426-72-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

产品类别：: 抑制剂

货号：: T3340

Product Introduction

Bioactivity

Name	SCR7
Description	SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).
Cell Research	SCR7 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3]. Wild-type, AAVS1TLR HEK293 and mouse NIH3T3 cells are maintained in DMEM supplied with 15% FBS, cells are passaged three times per week. The mouse Burkitt lymphoma cell line, generated from a Burkitt-like mouse lymphoma is maintained in DMEM supplied with 15% FBS, 2 mM HEPES, 2 mM sodium pyruvate, 2 mM L-glutamine, and 1× NAA, beta-mercaptoethanol and passaged four times per week. For puromycin selection, mCherry+ cells are sorted, seeded at 103 cells/well and selected with 3 mg/mL of Puromycin for 2 weeks. Then colonies are counted and single cells are sorted. The SCR7 inhibitor is purchased, 12 h after transfection these cells are maintained in complete medium supplied with 1 mM SCR7 inhibitor until analysis. At SCR7 concentrations of 60 mM and 10 mM, A reduction of transfection efficiency and of cell viability is observed[3].
Kinase Assay	Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software.
In vitro	在负荷Dalton's淋巴瘤的Swiss albino小鼠模型中,腹腔注射SCR7（20 mg/kg）不能够消退肿瘤.在BALB/c小鼠体内,腹腔注射SCR7（20 mg/kg）能够增强辐射,依托泊苷和3-氨基苯甲酰胺对于Dalton's淋巴瘤细胞的衍生瘤的细胞毒性作用.
In vivo	在MCF7细胞（IC50=40 μM）,A549细胞（IC50=34 μM）,HeLa细胞（IC50=44 μM）,T47D细胞（IC50=8.5 μM）,A2780细胞（IC50=120 μM）,HT1080细胞（IC50=10 μM）,和Nalm6细胞（IC50=50 μM）中,SCR7能够显著抑制细胞增殖。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 45 mg/mL (134.57 mM)
Keywords	gene \| end-joining \| nonhomologous \| SCR 7 \| DNA/RNA Synthesis \| Caspase 9 \| phosphorylation \| SCR7 \| CRISPR/Cas9 \| Caspase 3 \| ligase-IV \| SCR-7 \| inhibit \| replacement \| Apoptosis \| Inhibitor \| DNA \| anticancer
Inhibitors Related	Guanidine hydrochloride \| Metronidazole \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Thymidine \| Sodium 4-phenylbutyrate

SCR7|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 SCR7相关厂家报价

SCR7吡嗪
成都彼样生物科技有限公司 VIP
2024-11-22
询价

SCR7 (DNA ligase IV抑制剂)
碧云天生物技术有限公司
2024-11-22
询价

SCR7 (DNA ligase IV抑制剂)
上海康朗生物科技有限公司 VIP
2024-11-25
￥168

SCR7 1533426-72-0
成都彼样生物科技有限公司 VIP
2024-11-22
询价

内容声明